FDA notes study withdrawals, side effects with Rockwell's Triferic
This article was originally published in Scrip
Executive Summary
While FDA drug reviewers had their concerns about Rockwell Medical's Triferic (ferric pyrophosphate) ahead of a 6 November meeting of the agency's Oncologic Drugs Advisory Committee (ODAC) – most notably, missing data and imbalances in adverse events – investors were undeterred, and in fact, supportive.